Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort study

To the Editor: Immune-checkpoint inhibitors (ICIs) have revolutionized management of advanced cancer but are associated with significant toxicities. Cutaneous immune-related adverse events (cirAEs) have been associated with improved prognosis,1,2 but there is a lack of data on how the timing of cirAEs influences survival. We performed this study to investigate the impact of early-onset vs late-onset cirAEs on survival among immunotherapy recipients.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: Research letter Source Type: research